The FDA approved vorasidenib for the treatment of certain IDH-mutant diffuse gliomas, the first targeted therapy for these types of brain tumors. This oral inhibitor is for adults and children aged 12 or older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. Prior to this approval, patients had limited treatment options. The approval was based on the INDIGO trial, showing significant improvement in progression-free survival. Common side effects include fatigue, headache, COVID-19, musculoskeletal pain, diarrhea, nausea, and seizure. This approval is considered a major advancement in low-grade glioma treatment and could potentially delay the use of chemotherapy and radiation for many years.
Source link
FDA Approves Vorasidenib for Certain Gliomas
